Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Liver Disease

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cld.2017.06.007PMID 28987254
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.

  2017cited by this paper
• NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.

  2017cited by this paper
• Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.

  2016cited by this paper
• Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir‐containing regimen

  2016cited by this paper
• Advances in IBS 2016: A Review of Current and Emerging Data.

  2016cited by this paper
• Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies

  2016cited by this paper
• Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.

  2016cited by this paper
• L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.

  2016cited by this paper
• The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.

  2016cited by this paper
• Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

  2015cited by this paper
• Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy

  2015cited by this paper
• GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

  2015cited by this paper
• Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

  2015cited by this paper
• Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir

  2015cited by this paper
• Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.

  2015cited by this paper
• Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

  2015cited by this paper
• O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir

  2015cited by this paper
• P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial

  2015cited by this paper
• O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens

  2015cited by this paper
• P1332 : The astral studies: evaluation of SOF/GS-5816 single tablet regimen for the treatment of genotype 1–6 HCV infection

  2015cited by this paper
• P0895 : Comparison of three sequencing methods commonly used in hepatitis C virus resistance analysis: population-based vs. clonal vs. ultra deep sequencing

  2015cited by this paper
• Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

  2015cited by this paper
• Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

  2015cited by this paper
• Hepatitis C virus genetic variability and evolution.

  2015cited by this paper
• Hepatitis C virus drug resistance–associated substitutions: State of the art summary

  2015cited by this paper
• Update on hepatitis C virus resistance to direct-acting antiviral agents.

  2014cited by this paper
• Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

  2014cited by this paper
• Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: Novel insights about targeted genotyping approaches

  2014cited by this paper
• Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

  2014cited by this paper
• Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

  2014cited by this paper
• ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

  2014cited by this paper
• Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

  2014cited by this paper
• Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

  2014cited by this paper
• Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

  2014cited by this paper
• Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

  2014cited by this paper
• Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

  2014cited by this paper
• Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

  2014cited by this paper
• Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients

  2013cited by this paper
• Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource

  2013cited by this paper
• The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

  2012cited by this paper
• Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment

  2012cited by this paper
• Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.

  2012cited by this paper
• Resistance to direct antiviral agents in patients with hepatitis C virus infection.

  2010cited by this paper
• Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.

  2009cited by this paper
• Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients

  2008cited by this paper
• Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion.

  2004cited by this paper
• Replication of hepatitis C virus.

  2000cited by this paper
• Replication of the hepatitis C virus.

  2000cited by this paper
• Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

  1992cited by this paper

• Unraveling the mechanisms of Sofosbuvir resistance in HCV NS3/4A protease: Structural and molecular simulation-based insights.

  2024cites this paper
• Drug Interactions with Antiretroviral Medications

  2022cites this paper
• Drug Interactions with Antiretroviral Medications

  2022cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2020cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Is the conquest of Hepatitis C imminent?

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials.

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2019cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Hepatitis C Genotype 4 Virus NS3 and NS5A resistance Associated Substitutions in a 16 Year-Old Adolescent Failing Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin.

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications-Core Concepts

  2018cites this paper
• Drug Interactions with Antiretroviral Medications

  2017cites this paper